Iovance Biotherapeutics 주식 (NASDAQ: IOVA)

에 대한 최신 뉴스 Iovance Biotherapeutics (NASDAQ:IOVA) 주식

Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Asia

Mid Cap

News

Movers

ASTS

IOVA

LUMN

PSNY

SFTBF

SMTC

UPST

이들 10개의 중형주는 8월에 가장 좋은 성과를 보였다. 이 주식들이 귀하의 포트폴리오에 포함되어 있나요? 1. 폴스타 오토모티브 홀딩(NASDAQ:PSNY)의 주식이 8월에 74.19% 급등했다. 이는 2분기 강력한 인도량을 발표한 후 발생한 일이다.

AST 스페이스모바일 및 폴스타는 8월에 최고 성과를 보여준 10개 중형주 중 일부

BEAM

CLDX

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PEGA

PTGX

VKTX

VSAT

다음은 지난주 큰 폭의 상승세를 보인 6개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? AST 스페이스모바일(NASDAQ:ASTS)의 주가는 회사가 첫 5개의 상용 위성을 성공적으로 완료하면서 47.88% 상승했다.

비아샛 및 AST 스페이스모바일은 지난주 최고 성과를 보여준 6개 중형주 중 일부 (7월 21일-7월 27일)

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics Inc

Wells Fargo analyst Dori Kesten maintains Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) with a Equal-Weight and raises the price target from $13 to $14.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Pebblebrook Hotel, Raises Price Target to $14

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/25/final-trades-dominos-vertiv-mercado-libre-and-the-cowz.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington of Requisite Capital Management named Pacer US Cash Cows 100 ETF (CBOE: COWZ) as <a href="https://www.benzinga.com/quote/COWZ">her final trade</a>.
Joshua Brown of Ritholtz Wealth Management picked Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>).
A 13F filing from Nov. 14 showed that Berkshire Hathaway added a new stake. Buffett bought 1,277,256 shares of Ann Arbor, Michigan-based pizza chain Domino's Pizza. On Monday, TD Cowen analyst Andrew Charles maintained Domino&#8217;s Pizza with a Buy and raised the price target from&nbsp;$475&nbsp;to&nbsp;$515.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephen Weiss of Short Hills Capital Partners named Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) as his final trade.
On Oct. 23, Vertiv Holdings reported third-quarter results. Net sales rose 19% year-over-year to $2.074 billion, beating the consensus of $1.977 billion. Organic orders (excluding foreign exchange) rose 17%.
Joseph M. Terranova of Virtus Investment Partners picked MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>).
On Nov. 6, MercadoLibre reported quarterly earnings of $7.83 per share which missed the analyst consensus estimate of $10.78 per share. The company reported quarterly sales of $5.312 billion, which beat the analyst consensus estimate of $5.267 billion.
Price Action:
<ul>
<li>Pacer US Cash Cows 100 ETF gained 0.9% on Monday.</li>
<li>Domino&#8217;s shares were up 3.5% to settle at $469.18 during Monday's session.</li>
<li>Vertiv shares fell by 5.8% to close at $132.03 during Monday's session.</li>
<li>MercadoLibre gained by 4.7% to settle at $2,099.95 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42174548/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Long Ideas

Markets

Media

Trading Ideas

COWZ

MELI

Domino's, Vertiv, MercadoLibre And More On CNBC's 'Final Trades'

Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule
Top-line Data Expected in Q1 2025
THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) today announced the completion of patient enrollment in the PROGRESS&nbsp;(A&nbsp;Phase 2b, Dose-ranging,&nbsp;Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter&nbsp;Study with an Open-label Extension in PatientS&nbsp;with Diabetic Peripheral Neuropathic Pain)&nbsp;study evaluating LX9211, a novel, orally-delivered, selective investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1), for the treatment of diabetic peripheral neuropathic pain (DPNP).
The study successfully enrolled 494 patients, approximately 20 percent more than originally targeted, marking a significant milestone in the trial and increasing study power. Top-line data from PROGRESS is expected to be announced in Q1 2025.

Biotech

General

LXRX

Lexicon Announces Completion Of Enrollment In Phase 2B PROGRESS Study Of LX9211 In Diabetic Peripheral Neuropathic Pain; Strong Interest In Trial Participation Resulted In Enrollment Exceeding Target By 20% And Completion Ahead Of Schedule

Piper Sandler analyst Harsh Kumar reiterates Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Overweight and raises the price target from $60 to $75.

Reiteration

Piper Sandler Reiterates Overweight on Semtech, Raises Price Target to $75

Wells Fargo analyst Dori Kesten maintains Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) with a Equal-Weight and raises the price target from $14.5 to $16.

Wells Fargo Maintains Equal-Weight on Park Hotels & Resorts, Raises Price Target to $16

Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers announced today that the Company will be added to the Russell 2000&#xAE; Index as part of the planned fourth quarter IPO additions effective after the U.S market opens on December 23, 2024.
The Russell 2000&#xAE; Index measures the performance of the small-cap segment of the US equity market. The Russell 2000&#xAE; Index is a subset of the Russell 3000&#xAE; Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership. Initial public offerings (IPOs) are added to the Russell US&nbsp;indexes on a quarterly basis. For more information on the Russell 2000&#xAE; Index and the Preliminary List of IPO Additions: <a href="https://www.globenewswire.com/Tracker?data=q29mlhEHjPG4-JJKiqvqJ69erWXh6d1th8pPLVTMdHT0gsS1UTn94-1bQZQj5DJuYipgAZSFzu4xSQPePCsRVPXUe5N7dvNB32efdq3VBytEtK7MVN21MucRh_I6K5-32I-iTXRg0c-1Ff1JTQH_biP-5TGxJA9w8A-qL3H5J0qL2JCU00z13i-ElBKMC7WtFuGv2TJbkl4w3z-Y9G1ISw==">Russell US Index IPO additions and reports &#x7C; LSEG</a>

ACTU

Actuate Therapeutics To Be Added To Russell 2000 Index,  Effective After The U.S Market Opens On December 23, 2024

WIIM

DRUG

Bright Minds Biosciences shares are trading higher after Baird initiated coverage on the stock with an Outperform rating and announced a price target of $75.

Wells Fargo analyst Dori Kesten maintains Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) with a Overweight and raises the price target from $19 to $21.

Wells Fargo Maintains Overweight on Host Hotels & Resorts, Raises Price Target to $21

Maxeon to Focus Exclusively on U.S. Market, Executes Term Sheets with TCL Group to Address Rest-of-World Markets
SINGAPORE&nbsp;, Nov. 26, 2024 /PRNewswire/ -- Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) today announced a broad strategic restructuring of the Company's business portfolio and geographic market focus. Going forward, the Company intends to focus exclusively on the U.S. market where its market presence and planned local manufacturing footprint create a strong platform to drive growth and profitability. As a key part of this strategy, Maxeon has executed a five-year lease of an existing building in Albuquerque, New Mexico and plans to begin solar panel manufacturing in this 2 GW capacity facility in early 2026.&nbsp;

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Maxeon Announces A Broad Strategic Restructuring Of The Co's Business Portfolio And Geographic Market Focus. Going Forward, Intends To Focus Exclusively On The U.S. Market Where Its Market Presence And Planned Local Manufacturing Footprint Create A Strong Platform To Drive Growth And Profitability

ASPI

ASP Isotopes Completes Construction Of A Silicon-28 Facility In Pretoria, South Africa

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Michael Sison upgraded the rating for Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Equal-Weight to Overweight and boosted the price target from $110 to $125. Eastman Chemical shares closed at $105.84 on Monday. <a href="https://www.benzinga.com/quote/EMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Jeff Rulis upgraded the rating for First Interstate BancSystem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) from Neutral to Buy and raised the price target from $32 to $42. First Interstate BancSys shares closed at $35.47 on Monday. <a href="https://www.benzinga.com/quote/FIBK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst Jay Sole upgraded Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) from Neutral to Buy and increased the price target from $9 to $11. Hanesbrands Bank shares closed at $8.45 on Monday. <a href="https://www.benzinga.com/quote/HBI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo analyst Matthew Akers upgraded Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) from Equal-Weight to Overweight but lowered the price target from $157 to $147. Science Applications shares closed at $122.22 on Monday. <a href="https://www.benzinga.com/quote/SAIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim analyst Robert Drbul upgraded Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) from Neutral to Buy and announced a $30 price target. Capri shares closed at $21.54 on Monday. <a href="https://www.benzinga.com/quote/CPRI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying EMN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26080232/image-278-1024x572.png" alt="" class="wp-image-665275" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26080232/image-278-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26080232/image-278-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26080232/image-278-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26080232/image-278.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42174548/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Upgrades

Pre-Market Outlook

CPRI

FIBK

SAIC

This Eastman Chemical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) ("NFE" or the "Company") is pleased to announce the completion of the first step of the Company's $2.7 billion issuance of new senior secured notes due 2029 (the "Transaction").
The Transaction will be completed in two steps; the first step completed was the funding of $1.2 billion new senior secured notes. The second step will be an issuance and private exchange of $1.5 billion new senior secured notes expected to close during the first week of December for a total of $2.7 billion new notes issued that mature in November 2029.
As a result of the Transaction, the Company will achieve three key objectives:
<ul>
<li>Refinancing $2.4 billion of our existing bonds, including all bonds maturing in 2025 and more than two-thirds of our outstanding bonds maturing in 2026 and 2029</li>
<li>Extending the maturity of $900 million of the Company's $1 billion Revolving Credit Facility to October 2027 (effective once the second step of the transaction is completed)
<ul>
<li>Raising approximately $325 million in gross proceeds to provide additional liquidity for the Company</li>
</ul>
</li>
</ul>

Financing

New Fortress Energy Announces The Completion Of The First Step Of The Company's $2.7B Issuance Of New Senior Secured Notes Due 2029

Piper Sandler analyst Jessica Tassan reiterates Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) with a Overweight and raises the price target from $11 to $12.

HCAT

Piper Sandler Reiterates Overweight on Health Catalyst, Raises Price Target to $12

ASST

Asset Entities Acquires 50% Ownership Interest In Jeff Blue's 'Linkin Park Story, One Step Closer: From Xero to #1: Becoming Linkin Park'

Sonder Holdings Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SOND#NASDAQ">SOND</a>) ("Sonder" or the "Company") today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on November 20, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (the "Q3 Form 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Commission (the "SEC") on November 14, 2024. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC.
In accordance with Nasdaq's listing rules, the Company has 60 calendar days after the Notice to submit a plan to regain compliance with the Listing Rule. Following receipt of such plan, Nasdaq may grant an extension of up to 180 calendar days from the Q3 Form 10-Q's due date, or until May 19, 2025, for the Company to regain compliance. The Company intends to submit a compliance plan to Nasdaq and take the necessary steps to regain compliance with Nasdaq's listing rules as soon as practicable.
As previously disclosed, the filing of the Q3 Form 10-Q was delayed due to the matters described in the Form 12b-25, including to allow the Company sufficient time to complete its customary accounting and internal control processes and procedures. While the Company can provide no assurances as to timing, the Company will continue to work diligently to complete and file the Q3 Form 10-Q as soon as practicable. The Nasdaq also provided the Company with an amended compliance letter that does not include a requirement that it be subject to a Panel Monitor.

SOND

Sonder Holdings Receives Notification Of Deficiency From Nasdaq

Wells Fargo analyst Matthew Akers maintains Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) with a Overweight and lowers the price target from $230 to $205.

LDOS

Wells Fargo Maintains Overweight on Leidos Holdings, Lowers Price Target to $205

Dick's Sporting Goods shares are trading higher after the company reported better-than-expected Q3 financial results.

ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "Company" or "ParaZero"), an aerospace company focused on safety systems for defense and commercial drones and urban air mobility aircraft, announced today that it has partnering with Drone Nerds Inc., one of North America's largest enterprise drone solution providers. This collaboration marks a significant step forward in making ParaZero's innovative SafeAir Parachute Recovery System accessible to enterprise customers across industries as the Company expands its reach across in North America.
The ParaZero SafeAir System is designed to autonomously detect and mitigate flight risks in real-time. The system empowers drone operators with a robust safety solution to ensure mission continuity, even in the most complex operational environments.
By integrating flight pattern monitoring and autonomous response mechanisms, including parachute deployment and audible alerts, the SafeAir system safeguards people, property and valuable drone assets. Through this partnership, Drone Nerds will introduce SafeAir to a broader customer base, enhancing operational safety and compliance for enterprise users.

PRZO

ParaZero Partners With Drone Nerds To Expand SafeAir Systems Reach Across North America

<ul>
<li>SABCS&#xAE; "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes</li>
<li>Median <a href="https://feeds.issuerdirect.com/news-release.html?newsid=5433173071846618">overall survival of 13.4 months exceeds historical controls</a>. Phase 2 final median overall survival calculation is pending, as many patients remain alive</li>
<li>Potential identification of biomarkers to predict response</li>
<li>Five poster presentations to feature increased presence of cancer fighting CD8+ "killer" T cell in metastatic breast cancer tumors, response in central nervous system (CNS) metastases and additional Bria-IMT&#x2122; clinical data from the Phase 2 trial of Bria-IMT&#x2122; + immune check point inhibitor in metastatic breast cancer</li>
<li>Collaboration with the Medical College of Wisconsin will investigate use of Bria-IMT&#x2122; + CPI in any cancer patient with central nervous system (CNS) metastases &nbsp;</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 26, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be highlighting its positive overall survival and clinical benefit data in metastatic breast cancer (MBC) patients including those with CNS metastasis (not shown on the abstracts) who were treated with the Bria-IMT&#x2122; plus immune checkpoint inhibitor (CPI) combination in its "Spotlight" poster presentation session, at the 2024 San Antonio Breast Cancer Symposium&#xAE; (SABCS&#xAE;) held at Henry B. Gonzalez Convention Center, San Antonio, TX.

BCTX

TSX:BCT

BriaCell 2024 SABCS Spotlight Poster To Showcase Overall Survival Data Across All Patient Subtypes In Metastatic Breast Cancer; Median Overall Survival Of 13.4 Months Exceeds Historical Controls. Phase 2 Final Median Overall Survival Calculation Is Pending, As Many Patients Remain Alive

TOYO

TOYO shares are trading higher after the company announced a $150 million contract to supply solar cells to a solar manufacturer.

Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript

Iovance Biotherapeutics ( ($IOVA) ) has released its Q3 earnings. Here is a breakdown of the information Iovance Biotherapeutics presented to its i...

Iovance Biotherapeutics' Strong Q3 2024 Performance

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today and set a price target o...

Stifel Nicolaus Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)

JMP Securities analyst Reni Benjamin has reiterated their bullish stance on IOVA stock, giving a Buy rating on November 8. Reni Benjamin has given ...

Iovance Biotherapeutics: Promising Growth and Expansion in Cancer Treatment Fuels Buy Rating

Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity

Healthcare Analysts discuss the dynamics of an IOVA TIL Authorized Treatment Center on an Analyst/Industry conference call. to be held on November ...

JMP Securities healthcare analyst holds an analyst/industry conference call

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The company'...

TD Cowen Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 13,526 calls trading, 1.3x expected, and implied vol increasing over 11 points ...

Iovance Biotherapeutics call volume above normal and directionally bullish

High quality 'SMID-cap' stocks with cyclical exposure – MS

Iovance Biotherapeutics ( ($IOVA) ) has issued an update. Iovance Biotherapeutics is set to relocate its headquarters within the same building in S...

Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency

AGIO

AMRX

AROC

ASAN

ASGN

CARG

CEIX

DBRG

GBTG

GLNG

HWKN

IBRX

LBRT

OSCR

QDEL

SDRL

SKYW

SPTM

STRL

TBBK

TCBI

TGLS

TGNA

UMBF

USLM

WERN

Screenshot 2024-05-28 at 5.34.55 PM

CPMV

OTLC

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

Press Releases

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Health Care

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024

Earnings

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

Comments

Iovance Biotherapeutics

뉴스

에 대한 최신 뉴스 Iovance Biotherapeutics (NASDAQ:IOVA) 주식

일요일, 9월 08, 2024

월요일, 7월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌